Novosense(SH:688052)2025-04-29 13:28Financial Performance - The company's revenue for Q1 2025 reached ¥717,066,683.60, representing a 97.82% increase compared to ¥362,481,635.24 in the same period last year[4]. - Total operating revenue for Q1 2025 reached ¥717,066,683.60, a significant increase of 97.6% compared to ¥362,481,635.24 in Q1 2024[17]. - The net loss attributable to shareholders was ¥51,338,300.13, an improvement from a loss of ¥150,029,219.93 in the previous year[4]. - Net loss for Q1 2025 was ¥51,338,269.71, an improvement from a net loss of ¥150,029,219.93 in Q1 2024[18]. - Operating profit for Q1 2025 was -¥103,498,137.80, an improvement from -¥123,077,562.90 in Q1 2024[27]. - Net profit for Q1 2025 was -¥96,842,995.27, compared to -¥122,534,806.37 in Q1 2024, indicating a reduction in losses[28]. Cash Flow - The net cash flow from operating activities was negative at ¥170,200,915.43, a significant decline from a positive cash flow of ¥12,755,456.56 in the same period last year, primarily due to increased inventory and employee-related cash payments[4][9]. - Operating cash inflow for Q1 2025 was 666,158,045.57 RMB, a significant increase from 372,661,850.52 RMB in Q1 2024, representing an increase of approximately 78.8%[21]. - Operating cash outflow for Q1 2025 was 836,358,961.00 RMB, compared to 359,906,393.96 RMB in Q1 2024, resulting in a net cash flow from operating activities of -170,200,915.43 RMB[21]. - Cash flow from operating activities for Q1 2025 was -¥216,119,035.40, a decline from a positive cash flow of ¥36,144,148.71 in Q1 2024[30]. - The company reported cash and cash equivalents of ¥743,136,509.75 at the end of Q1 2025, down from ¥2,631,012,700.08 at the end of Q1 2024[31]. Research and Development - Research and development expenses totaled ¥178,681,849.20, accounting for 24.92% of revenue, a decrease of 17.03 percentage points from 41.95% in the previous year[5]. - Research and development expenses increased to ¥178,681,849.20 in Q1 2025, compared to ¥152,049,258.16 in Q1 2024, reflecting a growth of 17.5%[17]. - Research and development expenses increased to ¥178,131,638.26 in Q1 2025, up from ¥142,175,998.40 in Q1 2024, reflecting a focus on innovation[27]. Assets and Liabilities - Total assets at the end of the reporting period were ¥7,514,128,161.76, a decrease of 2.08% from ¥7,673,575,907.32 at the end of the previous year[5]. - Total assets decreased to ¥7,514,128,161.76 in Q1 2025 from ¥7,673,575,907.32 in Q1 2024, a decline of 2.1%[16]. - Total liabilities decreased to ¥1,594,059,369.19 in Q1 2025 from ¥1,726,461,672.37 in Q1 2024, a reduction of 7.7%[15]. - Total liabilities as of March 31, 2025, were 1,065,474,310.80 RMB, compared to 1,133,401,812.56 RMB in the previous year[26]. - The company's total equity decreased to ¥5,920,068,792.57 in Q1 2025 from ¥5,947,114,234.95 in Q1 2024, a decline of 0.5%[15]. Shareholder Information - Total number of common shareholders at the end of the reporting period is 7,626[11]. - The largest shareholder, Wang Shengyang, holds 15,487,920 shares, representing 10.87% of total shares[11]. - The second largest shareholder, Sheng Yun, holds 14,432,040 shares, representing 10.13% of total shares[11]. - The company has a total of 6,526,800 shares held by Suzhou Ruixi Information Consulting Partnership, accounting for 4.58%[11]. - The company has not reported any changes in the top 10 shareholders due to securities lending or borrowing[13]. - The company has not received any declarations of other related party relationships among the top shareholders[12]. Other Financial Metrics - The weighted average return on equity was -0.87%, an improvement from -2.43% in the previous year[4]. - The company reported non-recurring gains of ¥13,023,001.79 during the period, primarily from government subsidies and other non-operating income[7]. - The company reported a gross profit margin of approximately 34.0% for Q1 2025, compared to 31.0% in Q1 2024[17]. - Basic earnings per share for Q1 2025 were -0.36 RMB, compared to -1.05 RMB in Q1 2024[19].